Table 1 Ranges for S. pneumoniae and H. influenzae antimicrobial susceptibility ote: of companies theentioned in the results now. 36-47 months age group. ren: Potential implications for pneumococcal con
Antibiotic | Susceptible (S) (μg/mL) | Resistant (R) (μg/mL) |
|---|---|---|
S. pneumoniae | ||
Penicillin | ≤ 0.06 | ≥ 2 |
Cefotaxime | ≤ 0.06 | ≥ 4 |
Ceftriaxone | ≤ 0.06 | ≥ 4 |
Chloramphenicol | ≤ 2 | ≥ 32 |
Erythromycin | ≤ 0.06 | ≥ 1 |
Levofloxacin | ≤ 0.5 | ≥ 8 |
Linezolid | ≤ 2 | ≥ 4 |
Moxifloxacin | ≤ 0.25 | ≥ 4 |
Ofloxacin | ≤ 1 | ≥ 8 |
Tetracycline | ≤ 1 | ≥ 16 |
Trimethoprim/sulfamethoxazole | ≤ 0.5/9.5 | ≥ 16/304 |
Vancomycin | ≤ 1 | ≥ 2 |
H. influenzae | ||
Ampicillin | ≤ 1 | > 1 |
Amoxicillin-clavulanate | ≤ 1 | > 1 |
Cefotaxime | ≤ 0.12 | > 0.12 |
Cefuroxime | ≤ 1 | > 2 |
Cefuroxime axetil | ≤ 0.12 | > 1 |
Levofloxacin | ≤ 1 | > 1 |
Erythromycin | ≤ 0.5 | > 16 |
Tetracycline | ≤ 1 | > 2 |
Chloramphenicol | ≤ 1 | > 2 |
Trimethoprim-sulfamethoxazole | ≤ 0.5 | > 1 |